Diabetes and cancer II: Role of diabetes medications and influence of shared risk factors

Cancer Causes and Control

Volumn 23, Issue 7, 2012, Pages 991-1008

  Onitilo, Adedayo A ^a,b   Engel, Jessica M ^a   Glurich, Ingrid ^a   Stankowski, Rachel V ^a   Williams, Gail M ^b   Doi, Suhail A ^b  

^a MARSHFIELD CLINIC   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cancer; Diabetes; Meta analysis; Review

Indexed keywords

ACARBOSE; BIPHASIC INSULIN; DOXORUBICIN; GEMCITABINE; GLIBENCLAMIDE; GLICLAZIDE; GLITAZONE DERIVATIVE; GLUCOSIDASE INHIBITOR; HUMAN INSULIN; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; UNCLASSIFIED DRUG;

CANCER RISK; CANCER SURVIVAL; DEMOGRAPHY; DIET; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG POTENTIATION; ENVIRONMENTAL FACTOR; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84862486430     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-012-9971-4     Document Type: Review

References (148)

1. Chowdhury TA (2010) Diabetes and cancer. QJM 103(12): 905-915
2. Pollak M, Russell-Jones D (2010) Insulin analogues and cancer risk: cause for concern or cause celebre? Int J Clin Pract 64(5): 628-636
3. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29(2): 254-258 (Pubitemid 44106500)
4. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503):1304-1305 (Pubitemid 40813563)
5. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32(9):1620-1625
6. Landman GW, Kleefstra N, Van Hateren KJ, Groenier KH, Gans RO, Bilo HJ (2010) Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33(2):322-326
7. Monami M, Lamanna C, Marchionni N, Mannucci E (2008) Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 31(7):1455-1460
8. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16(4):1103-1123
9. Cannata D, Fierz Y, Vijayakumar A, LeRoith D (2010) Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med 77(2):197-213
10. Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC (2011) The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 15(4):825-836
11. Dehayem YM, Phelip JM, Kengne AP, Choukem SP, Benhamou PY, Halimi S (2011) Impact of diabetes mellitus on clinical presentation and prognosis of pancreatic cancer. Ann Endocrinol (Paris) 72(1):24-29
12. Osborne CK, Bolan G, Monaco ME, Lippman ME (1976) Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci USA 73(12): 4536-4540 (Pubitemid 8013935)
13. Masur K, Vetter C, Hinz A, Tomas N, Henrich H, Niggemann B, Zänker KS (2011) Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation. Br J Cancer 104(2):345-352
14. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M (2009) Insulin receptor expression by human prostate cancers. Prostate 69(1): 33-40
15. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM (2002) Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62(10):2942-2950 (Pubitemid 34525783)
16. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68(24):10238-10246
17. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915-928
18. Sichani MM, Yazdi FS, Moghaddam NA, Chehrei A, Kabiri M, Naeimi A, Taheri D (2010) Prognostic value of insulin- like growth factor-I receptor expression in renal cell carcinoma. Saudi J Kidney Dis Transpl 21(1):69-74
19. Levine AJ, Feng Z, Mak TW, You H, Jin S (2006) Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 20(3):267-275 (Pubitemid 43200281)
20. Zhao H, Dupont J, Yakar S, Karas M, LeRoith D (2004) PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23(3):786-794 (Pubitemid 38241279)
21. Qin L, Wang Y, Tao L, Wang Z (2011) AKT down-regulates insulin-like growth factor-1 receptor as a negative feedback. J Biochem 150(2):151-156
22. Vander HE, Lee SI, Bandhakavi S, Griffin TJ, Kim DH (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9(3):316-323 (Pubitemid 46344611)
23. Gray SG, Stenfeldt MI, De Meyts P (2003) The insulin-like growth factors and insulin-signalling systems: an appealing target for breast cancer therapy? Horm Metab Res 35(11-12):857-871 (Pubitemid 38058194)
24. De Meyts P (2004) Insulin and its receptor: structure, function and evolution. BioEssays 26(12):1351-1362
25. Chan JM, Stampfer MJ, Giovannucci E, Ma J, Pollak M (2000) Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. Growth Horm IGF Res 10 (Suppl A):S32-S33 (Pubitemid 30641926)
26. Gu F, Schumacher FR, Canzian F et al (2010) Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev 19(11):2877-2887
27. Thong MS, Van De Poll-Franse L, Hoffman RM, Albertsen PC, Hamilton AS, Stanford JL, Penson DF (2010) Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study. BJU Int 107(8):1223-1231
28. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE (2000) A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9(4):345-349 (Pubitemid 30265776)
29. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, Muti P, Lenner P, Koenig KL, Biessy C, Krogh V, Riboli E, Shore RE, Stattin P, Berrino F, Hallmans G, Toniolo P, Kaaks R (2004) Prediagnostic levels of C-peptide, IGF-I, IGFBP-1, -2 and -3 and risk of endometrial cancer. Int J Cancer 108(2):262-268 (Pubitemid 37541781)
30. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE (2000) Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60(14):3744-3748 (Pubitemid 32204562)
31. Diorio C, Pollak M, Byrne C, Mâsse B, Hébert-Croteau N, Yaffe M, Coté G, Bérubé S, Morin C, Brisson J (2005) Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14(5): 1065-1073 (Pubitemid 40656449)
32. Diorio C, Brisson J, Berube S, Pollak M (2008) Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev 17(4):880-888 (Pubitemid 351536419)
33. Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, Cheng I, Freedman ML, Hankinson SE, Hunter DJ, Colditz GA (2007) Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res 9(1):R18
34. Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23(6):824-854 (Pubitemid 35454590)
35. Ma J, Pollak M, Giovannucci E, Chan JM, Tao Y, Hennekens C, Stampfer MJ (2000) A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm IGF Res 10 (Suppl A):S28-S29 (Pubitemid 30641924)
36. Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak MN, Fuchs CS (2007) Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res 67(16):7923-7928 (Pubitemid 47281389)
37. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS (2009) Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27(2):176-185
38. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42-51 (Pubitemid 34032594)
39. Giovannucci E (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86(3):s836-s842
40. Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M (2008) Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res 14(24):8263-8269
41. Beck EP, Russo P, Gliozzo B, Jaeger W, Papa V, Wildt L, Pezzino V, Lang N (1994) Identification of insulin and insulin-like growth factor I (IGF I) receptors in ovarian cancer tissue. Gynecol Oncol 53(2):196-201 (Pubitemid 24177044)
42. Gliozzo B, Sung CK, Scalia P, Papa V, Frasca F, Sciacca L, Giorgino F, Milazzo G, Goldfine ID, Vigneri R, Pezzino V (1998) Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase-independent pathway. J Cell Biochem 70(2):268-280 (Pubitemid 28308935)
43. Papa V, Belfiore A (1996) Insulin receptors in breast cancer: biological and clinical role. J Endocrinol Invest 19(5):324-333 (Pubitemid 126450113)
44. Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92(18):1472-1489
45. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52(9):1766-1777
46. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A, Marchionni N, Rotella CM (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33(9):1997-2003
47. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52(9):1732-1744
48. Colhoun HM (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52(9):1755-1765
49. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52(9):1745-1754
50. Dejgaard A, Lynggaard H, Rastam J, Krogsgaard TM (2009) No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 52(12):2507-2512
51. Home PD, Lagarenne P (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52(12):2499-2506
52. Ljung R, Talbäck M, Haglund B, Joanasson JM, Gudbjörnsdò ttir S, Steineck G (2011) Insulin glargine use and short-term incidence of malignancies: a three-year population-based observation. Acta Oncol 50(5):685-693
53. Lind M, Fahlén M, Eliasson B, Odén A (2012) The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diabetes 6(1):53-59
54. Yang X, Ko GT, So WY, Ma RC, Yu LW, Kong AP, Zhao H, Chow CC, Tong PC, Chan JC (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 59(5):1254-1260
55. Vigneri R, Sava L, Squatrito S, Sciacca L (2010) Comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 59:1254-1260. Diabetes 59(11):e24
56. Simon D, Balkau B (2010) Comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 59:1254-1260. Diabetes 59(11):e25
57. Johnson JA, Gale EA (2010) Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem? Diabetes 59(5):1129-1131
58. Carstensen B (2010) Comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 59:1254-1260. Diabetes 59(9):e17-e18
59. Pocock SJ, Smeeth L (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374(9689):511-513
60. Yang X, So WY, Ma RC, Yu LW, Ko GT, Kong AP, Ng VW, Luk AO, Ozaki R, Tong PC, Chow CC, Chan JC (2010) Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 90(3):343-351
61. Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, Stalla GK, Schmid RM, Kales SN, Mantzoros CS (2011) Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 60(10): 1363-1371
62. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35(2):299-304
63. Bodmer M, Becker C, Meier C, Jick SS, Meier CR (2012) Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 107(4):620-626
64. Ben SI, Le Marchand-Brustel Y, Tanti JF, Bost F (2010) Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 9(5):1092-1099
65. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27(25):3576-3586 (Pubitemid 351793803)
66. Yan KH, Yao CJ, Chang HY, Lai GM, Cheng AL, Chuang SE (2010) The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Mol Carcinog 49(3):235-246
67. Rashid-Kolvear F, Taboski MA, Nguyen J, Wang DY, Harrington LA, Done SJ (2010) Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells. BMC Cancer 10:390
68. Ban JO, Oh JH, Son SM, Won D, Song HS, Han SB, Moon DC, Kang KW, Song MJ, Hong JT (2011) Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NF-kB via suppression of GSK-3beta expression. Cancer Biol Ther 12(4):288-296
69. Akinyeke TO, Stewart LV (2011) Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARgamma-independent mechanism. Cancer Biol Ther 11(12):1046-1058
70. Aguilar RB (2011) Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. Clin Ther 33(4):408-424
71. Ovalle F (2011) Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. Clin Ther 33(4):393-407
72. Azar M, Lyons TJ (2010) Diabetes, insulin treatment, and cancer risk: what is the evidence? F1000 Med Rep 2:pii4
73. Taubes G (2012) Cancer research. Cancer prevention with a diabetes pill? Science 335(6064):29
74. Bodmer M, Becker C, Meier C, Jick SS, Meier CR (2011) Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol 123(2):200-204
75. Bodmer M, Becker C, Meier C, Jick SS, Meier CR (2012) Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 21(2):280-286
76. Azoulay L, Dell'aniello S, Gagnon B, Pollak MN, Suissa S (2011) Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 20(2):337-344
77. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC (2011) Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2 + breast cancer. Ann Oncol (Epub ahead of print) 22 Nov 2011
78. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hus L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297-3302
79. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP (2007) Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25(12):1476-1481 (Pubitemid 46733074)
80. Koro C, Barrett S, Qizilbash N (2007) Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 16(5):485-492 (Pubitemid 46824269)
81. Ramos-Nino ME, MacLean CD, Littenberg B (2007) Association between cancer prevalence and use of thiazolidinediones: results from the vermont diabetes information system. BMC Med 5:17
82. Ferrara A, Lewis JD, Quesenberry CP Jr, Peng T, Strom BL, Van Den Eeden SK, Ehrlich SF, Habel LA (2011) Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 34(4):923-929
83. Taubes G (2012) Cancer research. Unraveling the obesity-cancer connection. Science 335(6064):30-32
84. Johnson JA, Bowker SL (2011) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetalogia 54(1):25-31
85. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E (2009) Sulphonylureas and cancer: a case-control study. Acta Diabetol 46(4):279-284
86. Tseng CH (2011) Diabetes and risk of bladder cancer: a study using the National Health Insurance Database in Taiwan. Diabetologia 54(8):2009-2015
87. van Staa TP, Patel D, Gallagher AM, de Bruin ML (2012) Glucose-lowering agents and the patterns of risk for cancer: a study with the general practice research database and secondary care data. Diabetologia 55(3):654-665
88. Pitocco D, Zaccardi F, Di Stasio E, Romitelli F, Santini SA, Zuppi C, Ghirlanda G (2010) Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud 7(1):15-25
89. Mena S, Ortega A, Estrela JM (2009) Oxidative stress in environmental- induced carcinogenesis. Mutat Res 674(1-2):36-44
90. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49(11):1603-1616
91. Dai Q, Gao YT, Shu XO, Yang G, Milne G, Cai Q, Wen W, Rothman N, Cai H, Li H, Xiang Y, Chow WH, Zheng W (2009) Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women's Health Study. J Clin Oncol 27(15): 2482-2488
92. Roberts CK, Sindhu KK (2009) Oxidative stress and metabolic syndrome. Life Sci 84(21-22):705-712
93. Hillon P, Guiu B, Vincent J, Petit JM (2010) Obesity, type 2 diabetes and risk of digestive cancer. Gastroenterol Clin Biol 34(10):529-533
94. Morrow JD (2000) The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 32(3-4):377-385
95. Basu S (2008) F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal 10(8):1405-1434
96. Hursting SD, Berger NA (2010) Energy balance, host-related factors, and cancer progression. J Clin Oncol 28(26):4058-4065
97. Cebioglu M, Schild HH, Golubnitschaja O (2008) Diabetes mellitus as a risk factor for cancer: stress or viral etiology? Infect Disord Drug Targets 8(2):76-87 (Pubitemid 351936177)
98. de Ferranti S, Mozaffarian D (2008) The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem 54(6):945-955
99. Gunter MJ, Leitzmann MF (2006) Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 17(3):145-156 (Pubitemid 43247408)
100. Endemann DH, Schiffrin EL (2004) Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus. Curr Hypertens Rep 6(2):85-89 (Pubitemid 39359547)
101. Chakraborty A, Chowdhury S, Bhattacharyya M (2011) Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract 93(1):56-62
102. Da Ros R, Assaloni R, Ceriello A (2004) The preventive antioxidant action of tiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabet Med 21(11): 1249-1252 (Pubitemid 39472383)
103. Qayyum R, Adomaityte J (2006) Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels. Am J Cardiol 97(5):655-658 (Pubitemid 43255034)
104. Monnier L, Colette C, Michel F, Cristol JP, Owens DR (2011) Insulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: a case for further study. Diabetes Metab Res Rev 27(4):348-353
105. Ezzati M, Henley SJ, Lopez AD, Thun MJ (2005) Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int J Cancer 116(6):963-971 (Pubitemid 41209205)
106. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J (2007) Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 298(22):2654-2664 (Pubitemid 350254957)
107. Foy CG, Bell RA, Farmer DF, Goff DC Jr, Wagenknecht LE (2005) Smoking and incidence of diabetes among US adults: findings from the Insulin Resistance Atherosclerosis Study. Diabetes Care 28(10):2501-2507 (Pubitemid 41384301)
108. Howard AA, Arnsten JH, Gourevitch MN (2004) Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med 140(3):211-219
109. Baliunas DO, Taylor BJ, Irving H, Roerecke M, Patra J, Mohapatra S, Rehm J (2009) Alcohol as a risk factor for type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 32(11):2123-2132
110. Wu D, Zhai Q, Shi X (2006) Alcohol-induced oxidative stress and cell responses. J Gastroenterol Hepatol 21 (Suppl) 3:S26-S29
111. Addolorato G, Leggio L, Ojetti V, Capristo E, Gasbarrini G, Gasbarrini A (2008) Effects of short-term moderate alcohol administration on oxidative stress and nutritional status in healthy males. Appetite 50(1):50-56 (Pubitemid 350086738)
112. de la Monte S, Derdak Z, Wands JR (2012) Alcohol, insulin resistance and the liver-brain axis. J Gastroenterol Hepatol 27(Suppl 2):33-41
113. Burge MR, Zeise TM, Sobhy TA, Rassam AG, Schade DS (1999) Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose. Diabetes Care 22(12):2037-2043 (Pubitemid 30433985)
114. LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S (2008) Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes 116(Suppl 1):S4-S6
115. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579-591 (Pubitemid 39025053)
116. Wotton CJ, Yeates DG, Goldacre MJ (2011) Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia 54(3):527-534
117. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280(5):E745-E751
118. Maritim AC, Sanders RA, Watkins JB III (2003) Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 17(1):24-38 (Pubitemid 36410972)
119. Kulie T, Slattengren A, Redmer J, Counts H, Eglash A, Schrager S (2011) Obesity and women's health: an evidence-based review. J Am Board Fam Med 24(1):75-85
120. La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B (2011) Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. Oncologist 16(6):726-729
121. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ (2008) Prediagnostic bodymass index, plasma C-peptide concentration, and prostate cancer- specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039-1047
122. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE (2006) Adult weight change and risk of postmenopausal breast cancer. JAMA 296(2):193-201 (Pubitemid 44050373)
123. Schienkiewitz A, Schulze MB, Hoffmann K, Kroke A, Boeing H (2006) Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 84(2): 427-433 (Pubitemid 44699156)
124. Wei M, Gaskill SP, Haffner SM, Stern MP (1997) Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/ hip ratio and other anthropometric measurements in Mexican Americans-a 7-year prospective study. Obes Res 5(1):16-23 (Pubitemid 127702765)
125. Gislette T, Chen J (2010) The possible role of IL-17 in obesity-associated cancer. Scientific World Journal 10:2265-2271
126. Holland WL, Summers SA (2008) Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 29(4): 381-402 (Pubitemid 351831506)
127. Cabarcas SM, Hurt EM, Farrar WL (2010) Defining the molecular nexus of cancer, type 2 diabetes and cardiovascular disease. Curr Mol Med 10(8):744-755
128. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109(3):433-438 (Pubitemid 38133916)
129. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569-578 (Pubitemid 351232031)
130. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J (2006) Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29(9):2102-2107 (Pubitemid 44871194)
131. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393-403 (Pubitemid 34437694)
132. Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, Mitchell P, Brand-Miller JC (2008) Glycemic index, glycemic load, and chronic disease risk-a meta-analysis of observational studies. Am J Clin Nutr 87(3):627-637 (Pubitemid 351364544)
133. Gallotta D, Nigro P, Cotugno R, Gazzerro P, Bifulco M, Belisario MA (2010) Rimonabant-induced apoptosis in leukemia cell lines: activation of caspase-dependent and -independent pathways. Biochem Pharmacother 80(3):370-380
134. Chuang HY, Chang YF, Hwang JJ (2011) Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase- 3 on human colorectal carcinoma-bearing animal. Biomd Pharmacother 65(4):286-292
135. Kontou N, Psaltopoulou T, Panagiotakos D, Dimopoulos MA, Linos A (2011) The mediterranean diet in cancer prevention: a review. J Med Food 14(10):1065-1078
136. Kastorini CM, Panagiotakos DB (2009) Dietary patterns and prevention of type 2 diabetes: from research to clinical practice; a systematic review. Curr Diabetes Rev 5(4):221-227
137. Kushi LH, Byers T, Doyle C, Bandera EV, McCullough M, McTiernan A, Gansler T, Andrews KS, Thun MJ; American Cancer Society 2006 Nutrition and Physical Activity Guidelines Advisory Committee (2006) American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 56(5):254-281 (Pubitemid 44527489)
138. Lee IM (2003) Physical activity and cancer prevention-data from epidemiologic studies. Med Sci Sports Exerc 35(11): 1823-1827
139. Meyerhardt JA, Giovannucci EL, Holmes MD, Chan AT, Chan JA, Colditz GA, Fuchs CS (2006) Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 24(22): 3527-3534 (Pubitemid 46630522)
140. Nathan DM, Buse JB, Davidson MB, Ferarannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1):193-203
141. Bloomgarden ZT (2011) American diabetes association postrgraduate meetings 2011. Diabetes Care 34(11):e164-e169
142. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA, Choudhry NK (2012) Patterns of medication initiation in mewly diagnosed diabetes mellitus: quality and cost implications. Am J Med 125(3): 302.e1-7
143. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225-249
144. Centers for Disease Control and Prevention (2011) National diabetes fact sheet: general information and national estimates on diabetes in the United States. Avialble at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf
145. Shaw LM (2011) The insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer. Cell Cycle 10(11): 1750-1756
146. Kazda C, Slieker L, Ilag L, Byrd R, Rees T, Prince M (2010) Appraising the mitogenicity of insulin analogues relative to human insulin-response to: Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activity in cultured cancer cells. Diabetes Metab Res Rev 2009; 25(1):41-49.
147. Diabetes Metab Res Rev 26(3):145-149
148. Dehal AN, Newton CC, Jacobs EJ, Patel AV, Gapstur SM, Campbell PT (2012) Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 30(1):53-59